期刊文献+

蛋白C通路在严重脓毒症炎症-凝血交叉对话中的作用及临床对策 被引量:5

原文传递
导出
摘要 脓毒症和脓毒性休克在国际范围内至今仍处于高发病率、高病死率状态。对其发病机理的进一步研究发现,重症患者炎症和凝血系统之间广泛的交叉对话导致病情恶性进展。目前研究的热点在于探讨机体应答反应的分子机制,发现蛋白C(PC)通路在其中发挥关键作用。重组人活化蛋白C(rhAPC)已获准用于严重脓毒症的临床治疗。本文就近年来有关蛋白C通路在脓毒症炎症-凝血交叉对话中的作用机制,以及rhARC在严重脓毒症中应用的临床研究结果与争议做一综述。
作者 林霞 于永慧
出处 《中华急诊医学杂志》 CAS CSCD 北大核心 2010年第11期1228-1230,共3页 Chinese Journal of Emergency Medicine
基金 山东省优秀中青年科学家科研基金(2006BS03065)
  • 相关文献

参考文献23

  • 1宋振举,郦珊珊,童朝阳,姚晨玲,孙湛,黄培志.脓毒症患者血清促炎和抗炎细胞因子的变化[J].中华急诊医学杂志,2008,17(11):1191-1194. 被引量:32
  • 2邓咏梅,樊晓东,薛晓艳,朱继红.低分子肝素治疗脓毒症的临床研究[J].中华急诊医学杂志,2008,17(2):132-136. 被引量:12
  • 3Levi M.The coagulant response in sepsis and inflammation[J].Hamostaseologie,2010,30(1):10-12,14-16.
  • 4王红,张淑文,任爱民,张丽霞,王超,黄樱,苏艳丽,王宝恩.重度脓毒症凝血功能紊乱与病情严重度及预后的关系[J].中华急诊医学杂志,2005,14(10):804-806. 被引量:54
  • 5Esmon CT.Crosstalk between inflamumation and thrombosis[J].Maturitas,2008,61(1/2):122-131.
  • 6Hagiwara S,Iwasaka H,Matsumoto S,et al.In vivo and in vitro effects of the anticoagulant,thrombomodulin,on the inflammatory response in rodent models[J].Shock,2010,33(3):282-288.
  • 7Schuepbach RA,Feistritzer C,Fernández JA,et al.Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1[J].Thromb Haemost,2009,101(4):724-733.
  • 8Dahlb? ck B,Villoutreix BO.The anticoagulant protein C pathway[J].FEBS Lett,2005,579(15):3310-3316.
  • 9Lay AJ,Liang Z,Rosen ED,et al.Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities[J].J Clin Invest,2005,115(6):1552-1561.
  • 10Galley HF,EI Sakka NE,Webster NR,etal.Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions[J].Br J Anaesth,2008,100(6):815-819.

二级参考文献35

  • 1唐邦清,黄大明,黄晖,韦干.低分子肝素早期干预预防感染性休克并发弥散性血管内凝血[J].临床荟萃,2005,20(5):281-282. 被引量:15
  • 2王红,张淑文,任爱民,张丽霞,王超,黄樱,苏艳丽,王宝恩.重度脓毒症凝血功能紊乱与病情严重度及预后的关系[J].中华急诊医学杂志,2005,14(10):804-806. 被引量:54
  • 3姚咏明,孟海东.严重脓毒症抗凝治疗的新认识[J].中华儿科杂志,2006,44(8):569-572. 被引量:12
  • 4岳茂兴.脓毒症的临床救治[J].中华急诊医学杂志,2006,15(12):1151-1152. 被引量:7
  • 5Shapiro NI, Howell M, Talmor D. A blueprint for a sepsis protocol [J]. Acad Emerg Med, 2005, 12 (4): 352-359.
  • 6American College of Chest Physicans/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [ J ]. Crit Care Med, 1992, 20 (6): 864-874.
  • 7Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS International sepsis definitions conference [ J ]. Crit Care Med, 2003, 31 (4) : 1250-1256 .
  • 8Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis [J]. N Engl J Med, 2001, 344: (10) 699-709.
  • 9Dellinger RP, Carler JM, Masur H, et al. Surviving sepsis campaign guidelines for management of sever sepsis and septic shock [ J ]. Intensive Care Med, 2004, 30 (4): 536-555.
  • 10Levi M, Jonge E, Poll T, et al. Novel approaches to the management of disseminated intravascular coagulation [ J ]. Crit Care Med, 2000, 28 (9 Suppl) : 20-24.

共引文献95

同被引文献109

引证文献5

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部